Navigation Links
Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
Date:5/21/2008

SOUTH EASTON, Mass., May 21 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that scientists from the New York University (NYU) School of Medicine, the Brooklyn Hospital Center, and the Harvard School of Public Health made presentations highlighting the advantages of the Company's patented pressure cycling technology (PCT) at three different scientific meetings earlier this week. There were three oral presentations and four poster presentations, all relating to research studies focused on cancer, stroke, obesity, biomarker discovery, and in-vitro fertilization.

BIOMARKER WORLD CONGRESS 2008 (Philadelphia, PA). Dr. Paul Pevsner (NYU School of Medicine) gave an oral presentation on Monday, May 19th on colon cancer. PCT was used by Dr. Pevsner and colleagues to extract proteins from colon tissue samples prior to analysis. Dr. Pevsner reported that new and additional proteins were extracted with PCT when compared to conventional extraction methods. Dr. Pevsner also reported that he and his colleagues were able to reduce the time required for preparing these proteins with trypsin for further analysis from 12 hours to under 45 minutes by using PCT, which he stated was a significant advantage over current techniques. Dr. Pevsner concluded that a change in the current paradigm of tumor diagnosis and staging may be needed, a paradigm in which PCT may play a pivotal role given the power of the technique to efficiently extract proteins from tissue samples and to subsequently quickly prepare them for downstream analysis.

GETTING OPTIMIZED TOOLS FOR DIAGNOSTICS (GOT Summit 2008 - Boston, MA). Dr. Alexander Ivanov (Harvard School of Public Health) gave an oral presentation on Tuesday, May 20th on the use of PCT and PCT-dependent reagents (ProteoSolve-LRS Kit) for the efficient recovery of proteins from lipid-rich adipose (fat) tissue. Adipose tissue plays a key role in several biomedical processes that are linked to obesity, insulin resistance, inflammation, and other physiological complications. Dr. Ivanov indicated that efficient and good quality analysis of adipose tissue is highly valuable in studies of these diseases. Adipose tissue is comprised of up to 80-90% lipid, which makes conventional detergent-based protein extraction methods inefficient and difficult. Dr. Ivanov found that the combination of PCT and ProteoSolve-LRS resulted in a much faster, less expensive, and higher quality extraction process, as compared to current methods.

ACS MID-ATLANTIC REGIONAL MEETING (MARM 2008 - New York, NY). Dr. Pevsner gave an oral presentation on Tuesday May 20th. In addition, he and his colleagues from the NYU School of Medicine and the Brooklyn Hospital Center also gave four poster presentations at this meeting. Dr. Pevsner's talk centered on the importance of sample preparation, and how the quality of sample preparation directly affects the quality of downstream results. Dr. Pevsner shared data illustrating the efficiency and quality of PCT results as compared to conventional methods in use today, and concluded that sample preparation using PCT resulted in a better quality extraction of proteins from tissue samples. On the same day, Dr. Pevsner and his colleagues delivered four poster presentations, which described the use of PCT in the extraction of proteins from breast and colon cancer tissue samples, as well as from the nutrient media used with in-vitro fertilization study procedures. The poster presentations reported that PCT increased protein yield and helped to identify proteins not previously seen in such samples. These presentations concluded that such enhanced extraction of proteins by PCT may result in new therapeutic strategies, diagnostic paradigms, and enhanced analysis of samples.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and higher) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the reported effectiveness of PCT to extract new proteins; the speed of sample preparation using PCT compared with current sample preparation methods; the importance of ProteoSolve-LRS and PCT in the reported identification of new proteins; the speed, cost, and quality advantages of ProteoSolve-LRS and PCT over other sample preparation methods; and the possibility that extraction of proteins by ProteoSolve-LRS and PCT may result in new therapeutic strategies, diagnostic paradigms, and enhanced analysis of samples. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT Sample Preparation System; the possibility that due to the nature of the research being performed, other laboratories may not find the use of ProteoSolve-LRS and PCT to be as advantageous as reported by Dr. Ivanov and by Dr. Pevsner and his colleagues; due to scientific and medical challenges, the possibility that the data generated by Dr. Ivanov, and by Dr. Pevsner and his colleagues, or that may be generated by other researchers in the future, may not be beneficial in the development of new therapeutics and diagnostics for breast and colon cancer, IVF, stroke, or other procedures and diseases; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.

Edward H. Myles, Senior Vice President (508) 230-1828 (T)

of Finance & CFO


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Seven-Year Neck Pain Study Sheds Light on Best Care
2. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
3. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
4. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
5. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
6. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
7. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
8. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
11. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Walgreens has committed to ... states and Washington, D.C. as part ... that was commended by shareholder advocacy organization As You Sow. ... You Sow. "Many people hold on to unneeded drugs because ... have tragic consequences." --> Conrad MacKerron , ...
(Date:2/11/2016)... , Feb. 11, 2016  NOIT™ Research LLC, a ... "Gift of Change" campaign to assist needy families in ... such unit sold between February 10, 2016 and March ... a needy family. The NOIT is an auditory stimulus ... individuals develop language skills. Beth Shier ...
(Date:2/11/2016)... and PORTLAND, Ore. , ... 340B optimization company, is pleased to announce the acquisition ... sole community and rural access hospitals. Along with providing ... of 340B consulting services to assist clients in navigating ... R. Love , CEO of Wellpartner. --> ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... , ... In the early or “honeymoon” stage of a relationship, couples strive ... their way to be romantic, and may exaggerate a strength or two in an ... profile. , A recent study from Queendom.com , however, suggests that new ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of ... Evangeline Parishes. The purpose of these scholarships is to encourage applicants to pursue ... to seek employment within these two parishes. , “We have available jobs in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination Drug ... p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination products ... increased attention from all stakeholders in the development of new chemical entities. , ...
(Date:2/12/2016)... ... 2016 , ... T.E.N., a technology and information security executive ... Awards 2016. Finalists and winners of the ISE® Awards for both Executive and ... Gala on March 15, 2016 at the Westin Peachtree Plaza, Atlanta. , ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and ... J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA ... Southern Nevada Healthcare System. This will be the first Fisher House in Nevada, ...
Breaking Medicine News(10 mins):